

3D Human Retinal Microvascular Angiogenesis

Product Name: 3D Human Retinal
Microvascular Angiogenesis
Catalog #: 3D45004
Format: 6, 12, or 24 wells
Storage: 37°C




This product is produced for research use only. **Caution:** Proper precautions must be taken to avoid exposure. Always wear proper protective equipment (Gloves, safety glasses, etc.) when handling these materials. We recommend following the universal procedures for handling products of human origin as the minimum precaution against contamination.

GENERAL INFORMATION

Retinal microvascular morphogenesis is a complex and highly coordinated process, which occurs during embryonic development, postnatally and in association with several visually-impairing diseases, including retinopathy of prematurity (ROP), age-related macular degeneration and diabetic retinopathy.

Retinal vascular formation is a complex process that requires a precise temporospatial regulation of various elements, including the growth factors. Insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) are ligands of specific receptor tyrosine kinases (RTKs), which, if activated, will initiate downstream pathways that ultimately promote cell survival, cell proliferation, vascular permeability and cell migration; all of which permit blood vessel development. Formation of blood vessels from pre-existing vessels may be normal (angiogenesis) or pathological (neovascularization) processes.

Our 3D Human Retinal Microvascular Angiogenesis model is constructed using GFP-Tagged human Retinal Microvascular Endothelial cells. They are co-cultured with RFP-Tagged human supporting cells. GFP positive human retinal capillary like tubule formation can be monitored in real time under fluorescence microscope throughout the whole process of the experiment.



FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
Phone 866-350-1500 • fax 612-677-3976 • email: pshuster@neuromics.com

Advantages:

1. Cells used in the 3D model are all human cells; results obtained are more relevant to human situations rather than those data from animal models, i.e. CAM et al.
2. The whole angiogenesis process can be monitored (from cell inoculation to the end of experiment) therefore, more crucial information can be acquired at multiple time points from a single experiment.
3. No need to perform post--experimental staining for endothelial markers, this is particularly important, if those markers are changed in experimental conditions involved in the studies.

The 3D Human Retina Microvascular Angiogenesis model contains all of the materials necessary to perform multiple angiogenesis assays in 6, 12, or 24 well formats. The 3D model is designed that the testing materials, i.e. compounds, conditioned media, or tissue explants, can be added into the system at any time, ranging from the onset of vasculogenesis to advanced angiogenesis. The resulting effect on tubule formation (tubular length, number of branches et al) can be monitored throughout the whole process under inverted fluorescence microscope.

Introduction:

Angiogenesis is a multistep process whereby new blood vessels develop from preexisting vasculature. Angiogenesis plays a key role in numerous physiological and pathological processes and understanding the mechanism of angiogenesis will therefore provide new approaches to the treatment of a wide range of pathologies. Angiogenesis is a complex process in which the following events are believed to play a critical role:

- Proteolytic degradation of the extracellular matrix
- Directed migration of endothelial cells
- Proliferation of endothelial cells
- Deposition of new extracellular matrix
- Formation of tubules and anastomosis of the newly formed vessels.

The 3D Human Retinal Microvascular Angiogenesis Kit series products from Neuromics is a proprietary system in which GFP-tagged human endothelial cells from variable vascular beds are co-cultured with RFP-tagged human supporting cells in a specially designed medium. The endothelial cells initially form small islands within the culture matrix. They subsequently begin to proliferate and then enter a migratory phase during which they move through the matrix to form threadlike tubule structures with lumens. They gradually join up (by 1 - 2 weeks) to form a network of anastomosing tubules which closely resembles the capillary bed found in vivo. 3D Human Retinal Microvascular Angiogenesis Kit contains all of the materials necessary to perform multiple angiogenesis assays in a 24-well format. The kit is designed so that the testing materials, i.e. compounds, conditioned media, or tissue explants, can be added into the system at any time, ranging from the onset of

FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
Phone 866-350-1500 • fax 612-677-3976 • email: pshuster@neuromics.com

vasculogenesis to advanced angiogenesis. The resulting effect on tubule formation (tubular length, number of branches et al) can be monitored throughout the whole process under inverted fluorescence microscope.

Reagents and Materials Provided:

- (1) 1 x vial of mixture of GFP-tagged Human Retina Microvascular ECs and RFP-tagged human supporting cells (-80°C or liquid N2)
- (2) 1 x 24-well AlphaBio coated plate (Room temperature, for 2 months)
- (3) 1 x 500ml of Endo-Growth Medium (4°C)

Protocols:

Day 1

1. Pre warm Endo-Growth Medium to 37°C in a water bath
2. Accurately pipette 24ml Endo-Growth Medium into a 50ml Falcon tube
3. Rapidly thaw the vial of cryopreserved cells in a 37°C water bath
4. Transfer all cells gently into 24ml pre warmed Endo-growth medium
5. Mix well the cells gently using a serological pipette
6. Add 1.0ml of cell suspension to each well of the pre coated 24-well plate.
7. Make sure the cells are evenly dispersed in the wells.
8. Place the plate in an incubator (37°C, 5% CO2 and humidified)

Day 2


9. Take the plate from the incubator and examine cells under inverted fluorescence microscopy (GFP positive Human Retina Microvascular ECs should sparsely and evenly distributed among RFP positive human mesenchymal supporting cells).
10. Wash the cells once with 2 ml of PBS
11. Add 2.0ml of fresh Endo-Growth medium (control) or Experimental media (EndoGrowth medium, plus pro- or anti-angiogenic reagents according to customer's needs).
12. Place the plate back into the incubator. Day 4, 6, 8, 10, 12, and 14..... 13. Replace the medium every 2 days until the end of the experiments.

FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
Phone 866-350-1500 • fax 612-677-3976 • email: pshuster@neuromics.com



FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. v1-09809

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
 Phone 866-350-1500 • fax 612-677-3976 • email: pshuster@neuromics.com